Compare Mesoblast Limited (MESO) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Mesoblast Limited trades at $16.38 (market cap $2.17B), while iShares 20 Plus Year Treasury Bond ETF trades at $83.62. The key difference: Mesoblast Limited is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| MESO | TLT | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | — |
52-Week High | $20.96 | $92.06 |
52-Week Low | $12.88 | $83.02 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $36 million for Ryoncil, showing strong commercial progress, but maintains a net income margin of -144.33% with significant losses. Recent news highlights pivotal Phase 3 trial milestones for chronic low back pain treatment and a $50 million non-dilutive financing draw.
Outlook is mixed: bullish analyst sentiment and clinical advancements offer upside potential, but high cash burn and persistent losses pose substantial risks. Investors should weigh the company's growth trajectory against its financial sustainability and regulatory milestones.
TLT trades at $83.66, down 1.02% on the day, with a bearish technical outlook as moving averages signal strong selling pressure. The ETF has experienced significant investor attention amid fixed income market resurgence, with recent dividend payments of $0.32-$0.34. Long-term Treasury bonds face headwinds from inflation concerns and potential Fed policy shifts, though current yields offer improved income potential compared to pre-crisis levels.
TLT presents a contrarian opportunity with starting yields four to five times higher than pre-2022 levels, but faces duration risk if interest rates remain elevated. The ETF's performance remains sensitive to Federal Reserve policy decisions and inflation trajectory, with institutional flows indicating renewed interest in fixed income assets despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
